4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:June 23, 2022 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:June 22, 2022 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
SC TO-I: Tender offer schedule and amendment filed by the issuer. Post author:andrewkaretas Post published:June 21, 2022 Post category:SEC Filings Allogene Therapeutics, Inc. Continue ReadingSC TO-I: Tender offer schedule and amendment filed by the issuer.
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:June 17, 2022 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:June 17, 2022 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:June 17, 2022 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:June 17, 2022 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:June 17, 2022 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
4: Statement of changes in beneficial ownership of securities Post author:andrewkaretas Post published:June 17, 2022 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading4: Statement of changes in beneficial ownership of securities
8-K: Report of unscheduled material events or corporate event Post author:andrewkaretas Post published:June 17, 2022 Post category:SEC Filings Allogene Therapeutics, Inc. Continue Reading8-K: Report of unscheduled material events or corporate event
